Review of clinic trials: Agents targeting c-Met

Reviews on Recent Clinical Trials

Volumn 2, Issue 2, 2007, Pages 143-147

  Abidoye, Oyewale ^a,b   Murukurthy, Nadh ^a,b   Salgia, Ravi ^a,b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b University of Chicago   (United States)

Author keywords

c Met receptor tyrosine kinase; Hepatocyte growth factor; mTOR pathway; RTK catalytic activity; XL184

Indexed keywords

AMG 102; ARQ 197; HPK 56; MGCD 265; MONOCLONAL ANTIBODY; MP 470; NEUTRALIZING ANTIBODY; PHA 665752; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RIBOZYME; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SU 11274; UNCLASSIFIED DRUG; XL 184; XL 880;

ADVANCED CANCER; ANOREXIA; BIOCHEMISTRY; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG MECHANISM; DRUG TARGETING; EDEMA; ENZYME ACTIVATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; META ANALYSIS; METASTASIS; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUTROPENIA; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 34248681295     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488707780599357     Document Type: Review

References (26)

1. Hahn O, Salgia R. Novel therapies in lung cancer. Hematol Oncol Clin N Am 2005; 19; 343-67.
2. Sattler M, Salgia R. c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy. Curr Oncol Rep 2007; 9(2): 102-8.
3. Ma PC, Jagadeeswaran R, Jagadessh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interference RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479-88.
4. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006; 12(12): 1292-8.
5. Ma PC, Gautam M, Christensen JG, Salgia R. c-Met: Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309-25.
6. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinoma. Nat Genet 1997; 16: 68-73.
7. Zhuang Z, Park WS, Pack S, et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal cell carcinomas. Nat Genet 1998; 20: 66-9.
8. Sakakura C, Mori T, Sakabe T, et al. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer 1999; 24: 299-305.
9. Matsumoto K, Nakamura T. Mechanisms and significance of bi-functional NK4 in cancer treatment. Biochem Biophys Res Commun 2005; 333: 316-27.
10. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66: 1721-9.
11. Bowers DC, Fan S, Walter K, et al. Scatter factor/hepatocyte growth factor activates AKT and protects against cytotoxic death in human glioblastoma via PI3-kinase and AKT-dependent pathways. Cancer Res 2000; 60: 4277-83.
12. Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003; 88: 408-17.
13. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63: 6272-81.
14. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-Met inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005; 11: 2312-9.
15. Kim SJ, Johnson M, Koterba Y, Herynk MH, Uehara H, Gallick GE. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res 2003; 9: 5161-70.
16. Amgen 102 Investigator's Brochure, version 2.0 Thousand Oaks, CA: Amgen Inc.; July 2006
17. Genetic Engineering News. Methylgene selects multitargeted kinase 'c-Met' clinical candidate for oncology. http://www.genengnews.com/news/ bnitem.aspx?name=9881849, Accessed February 28, 2007.
18. Rosen L, Garcia A, Mulay M, et al. A phase 1 dose escalation study of ARQ 197, a selective inhibitor of the cMet receptor in patients with metastatic solid tumors. Eur J Cancer 2006; suppl 4: 196 (abstract 651).
19. ARQ 197 interim analysis update 2006. Accessed February 28, 2007 www.genengnews.com/news/bnitem.aspx?name=8568524&taxid=9.
20. LoRusso P, Appleman L, Zhu A, et al. Pharmacodynamics of XL880, a novel spectrum selective kinase inhibitor (SSKI), administered orally to patients with advanced solid tumors. Eur J Cancer 2006; suppl 4: 124 (abstract 404).
21. XL880 update 2006. Accessed February 28, 2007 http://www.medicalnewstoday.com/medicalnews.php?newsid=59741.
22. Company Boardroom: Exelixis initiates phase II trial of XL880 in patients with papillary renal cell carcinoma. Exelixis Inc. Accessed, March 1, 2007 http://ccbn.aol.com/releasetext.asp?ticker=exel&coid= 120923&client=aol&release=876972.
23. Company Boardroom: Exelixis initiates phase II trial of XL880 in patients with gastric cancer. Exelixis Inc. Accessed March 1, 2007. http://ccbn.aol.com/releasetext.asp?ticker=exel&coid= 120923&client=aol&release=944502.
24. Kurzrock R, Camacho L, Hong D, et al. A phase I dose-escalation study of the safety and pharmacokinetics of XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies. Eur J Cancer 2006; suppl 4: 124 (abstract 405).
25. XL184 update 2006; Accessed February 28, 2007 http://www.medicalnewstoday.com/medicalnews.php?newsid=56351.
26. Welsh J, Mahadevan D, Dougherty G. et al. c-Met inhibition radio-sensitizes melanoma by inhibiting double strand DNA repair. Eur J Cancer 2006; suppl 4: 161 (abstract 532).